(Press-News.org)
The fusion of artificial intelligence (AI)-enabled technologies and precision oncology is advancing at an unprecedented pace, and the introduction of the new peer-reviewed journal, AI in Precision Oncology, will support clinicians, researchers, AI experts, patients, and industry leaders with up-to-date advancements in the field while fostering an environment conducive to further innovation and collaboration. A preview issue of the journal is now available. Click here to read the issue now.
“At the heart of my vision for this journal is the unwavering belief that AI can help make care more human," Editor-in-Chief Douglas Flora, MD, writes in his opening Editorial. “AI in Precision Oncology is more than just a scientific or medical journal; it is a mission-driven initiative to harness the power of AI in improving oncology care. In the process, we aim to shape an AI-enabled health care system that is equitable, efficient, and patient centered—making health care more human.”
The preview issue includes an interview with Dr. Flora, conducted by Damian Doherty, Editor-in-Chief of Inside Precision Medicine. In the interview, Dr. Flora, who is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare in northern Kentucky, discusses his clinical and leadership roles and his conviction that AI will revolutionize the practice of oncology.
In the Commentary titled “’We’re Doing it Wrong!’ Phenomics and Hyperscale AI for Health Care,” Leroy Hood, MD, PhD, from the Institute for Systems Biology, and Scott Penberthy, PhD, from Google Cloud, contend that phenomics is the game changer. “Phenomics takes everything we know about your body—your genes, quantification of the proteins and metabolites in your blood, the tiny microbes living in your gut, even the heart rate and distance data from your smartwatch—and blends its data together to create a predictive picture of you.”
Scott Penberthy, PhD, authored a Commentary titled “What is Artificial Intelligence? An Insight for Oncologists.” This is the first in what will be a series of articles describing AI, its capabilities, and its applications in oncology.
“Prompt Assistance” will be a regular column in AI in Precision Oncology dedicated to highlighting and recommending specific applications of AI tools such as ChatGPT in clinical practices. In this issue, Dr. Flora and Nikhil Thaker, from Capital Health Radiation Oncology, contributed the article titled “Designing Prompts for Generative Artificial Intelligence in Clinical Oncology Contexts.” They present ten key guidelines to assist users get the best out of their AI queries.
In the Commentary titled “Realizing the Promise of Tumor Infiltrating Lymphocytes as a New Biomarker for Personalized Medicine May Require the Power and Precision of Artificial Intelligence,” Michael Montalto, from PathAI, discusses the use of AI algorithms to analyze large datasets of histological stains and quantify the density and distribution of immune cells within the tumor microenvironment.
An original research article titled “AI-Augmented Clinical Decision Support in a Patient-Centric Precision Oncology Registry” was contributed by Mark Shapiro, from xCures, Inc. and coauthors. The authors describe xDECIDE, a clinical decision support system that is accessed through a web portal and powered by a “Human-AI Team,” which offers oncology healthcare providers with treatment options personalized for their cancer patients and outcomes tracking.
Pranali Pachika, MD, from the University of Louisville, and coauthors, contributed the Review article titled “The Use of Artificial Intelligence in Lung Cancer Management.” Treatment for lung cancer is highly individualized. The authors describe how artificial intelligence components such as machine learning and deep learning can be applied in all stages of lung cancer, including screening, diagnosis, therapy selection, prognosis, and surveillance.
To request a print copy of the preview issue, click here.
About the Journal
AI in Precision Oncology is the only peer-reviewed journal dedicated to the advancement of artificial intelligence applications in clinical and precision oncology. Spearheaded by Editor-in-Chief Douglas Flora, MD and supported by a diverse and accomplished team of international experts, the Journal provides a high-profile forum for cutting-edge research and frontmatter highlighting important research and industry-related advances rapidly developing within the field. For complete information, visit the AI in Precision Oncology website.
About the Publisher
Mary Ann Liebert, Inc. is a global media company dedicated to creating, curating, and delivering impactful peer-reviewed research and authoritative content services to advance the fields of biotechnology and the life sciences, specialized clinical medicine, and public health and policy. For complete information, please visit the Mary Ann Liebert, Inc. website.
END
The U.S. Air Force Office of Scientific Research has funded a new Multi-University Research Initiative to be led by Yuliy Baryshnikov, a professor of mathematics and electrical & computer engineering at the University of Illinois Urbana-Champaign. The initiative, Hybrid Dynamics – Deconstruction and Aggregation, or HyDDRA, will bring researchers from four universities together to address the problem of hybrid control using modern mathematical tools.
The initiative will be funded with an award ...
Jonathan Middleton, DMA, a professor of music theory and composition at Eastern Washington University, is the lead author of a newly published study demonstrating how the transformation of digital data into sounds could be a game-changer in the growing world of data interpretation.
The analysis was conducted over three years with researchers from the Human-Computer Interaction Group at Finland’s Tampere University.
Recently published in the peer-review journal Frontiers in Big Data, Dr. Middleton’s research paper examines how he and his co-investigators were primarily concerned with showing ...
As the wind and rain pound the blades of a wind turbine, UBC Okanagan researchers carefully monitor screens, hundreds of kilometres away analyzing if the blade’s coatings can withstand the onslaught.
While this was only a test in a lab, the researchers are working to improve the way structures such as turbines, helicopter propellers and even bridges are monitored for wear and tear from the weather.
A changing climate is increasing the need for better erosion-corrosion monitoring in a wide range of industries from aviation to marine transportation and from renewable energy generation to construction, explains UBC Okanagan doctoral student Vishal Balasubramanian.
In ...
REDWOOD CITY, Calif. (October 18, 2023) — Today, the Chan Zuckerberg Initiative (CZI) announced the launch of a new biomedical research hub in New York City that will catalyze collaboration between leading scientific and technology institutions in the area, with the goal of solving grand scientific challenges on 10- to 15-year time horizons. The Chan Zuckerberg Biohub New York (CZ Biohub NY) brings together Columbia University, The Rockefeller University, and Yale University to create new technologies to characterize and bioengineer immune cells — with the ultimate ...
ITHACA, N.Y. -- Cornell researchers have harnessed the power of baker’s yeast to create a cost-effective and highly efficient approach for unraveling how plants synthesize medicinal compounds, and used the new method to identify key enzymes in a kratom tree.
Aspirin, morphine and some chemotherapies are examples of drugs that are derived from natural compounds produced by plants. Understanding how a plant creates such compounds usually begins with analyzing plant transcriptomes to identify up to hundreds of genes that could potentially code for the enzymes that work together ...
During the COVID-19 pandemic, eviction moratoria prevented or delayed many people from experiencing homelessness. But now that the pandemic is over and the short-term eviction protection has ended, the number of evictions and cost of basic needs have increased. Daphne Hernandez, PhD, associate professor in the Department of Research with Cizik School of Nursing at UTHealth Houston, is studying how varying periods of eviction protection that people experienced during the pandemic is associated with psychosocial ...
A five-year, $6.4 million grant to develop an integrated, multiscale artificial intelligence (AI) approach to study genetic factors associated with Alzheimer’s disease has been awarded to UTHealth Houston by the National Institute on Aging, part of the National Institutes of Health.
A team led by Zhongming Zhao, PhD, and Xiaoqian Jiang, PhD, principal investigators and professors at McWilliams School of Biomedical Informatics at UTHealth Houston, are developing a deep-learning AI system to link brain imaging with cell-specific ...
SAN ANTONIO — October 18, 2023 —On November 2, Dr. Alan Stern, planetary scientist and associate vice president of Southwest Research Institute’s Space Science Division, will fly aboard the Virgin Galactic commercial spaceship VSS Unity on a suborbital space mission to train for a future NASA-funded Virgin Galactic suborbital flight in which he will perform two NASA experiments in space.
“When I was a kid, human spaceflight was only available to NASA astronauts and Russian cosmonauts. Now that’s changing, and SwRI is pioneering a new era of space research being conducted in space, by space scientists,” Stern ...
Knee and hip replacements are increasing globally due to an ageing population. In the United States, the number of patients needing a joint replacement will exceed 2.7 million in the next 7 years. Post-surgery infections, while rare at 1-5% of patients, result in high patient morbidity and mortality.
In the United States the annual national hospital costs for treating infection are projected to exceed $1.85 billion.
We currently use an antibiotic, cefazolin, at the time of surgery to prevent infection. But with the rise of antibiotic resistant bacteria, experts ...
Cedars-Sinai Cancer investigators have identified two promising new treatment options for men with recurrent prostate cancer—both of which helped patients live longer without their disease progressing than the current standard treatment. The results of their international Phase III clinical trial were published today in the New England Journal of Medicine.
“If these treatments are approved by the Food and Drug Administration, our results will be practice changing,” said Stephen Freedland, MD, associate director for Training and Education and the Warschaw, Robertson, ...
